Dr. Christopher M. Johnson, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 280
Licensed in Texas since 2012, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TX license P4767 (first issued 2012; active) -
Internal Medicine Physician
TX license BP10041332 · TX license P4767 (first issued 2012; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White Medical Center - Temple Temple, TX
- Baylor Scott & White Medical Center - Round Rock Round Rock, TX
- Baylor Scott & White Medical Center Hillcrest Waco, TX
- Baylor Scott & White Medical Center- College Stati College Station, TX
Medical groups
- Scott and White Clinic (2,461 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 280
- Services billed
- 456
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 100 | 76 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 79 | 79 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 43 | 43 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 40 | 40 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 34 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 16 |
| Biopsy of large bowel using a flexible endoscope | 16 | 16 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 14 | 11 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Humira(Cf) Pen (adalimumab) Other prescribers in Temple, TX | 81 |
| Omeprazole Other prescribers in Temple, TX | 71 |
| Famotidine Other prescribers in Temple, TX | 69 |
| Mesalamine Other prescribers in Temple, TX | 66 |
| Stelara (ustekinumab) | 64 |
| Pantoprazole Sodium Other prescribers in Temple, TX | 61 |
| Dicyclomine Hcl Other prescribers in Temple, TX | 47 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Temple, TX | 28 |
| Colestipol Hcl Other prescribers in Temple, TX | 26 |
| Prednisone Other prescribers in Temple, TX | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 8 payments worth $455 in total to this clinician.
| AbbVie Inc. | $136 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $122 |
| Janssen Biotech, Inc. | $89.00 |
| Madrigal Pharmaceuticals | $45.29 |
| Medtronic, Inc. | $28.56 |
| Novo Nordisk Inc | $20.08 |
| Celltrion USA Inc. | $14.86 |
| Food and Beverage | $366 |
|---|---|
| Education | $89.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 23, 2025 | Education TREMFYA · Immunology · in-kind | $89.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $69,686 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2)
Genentech, Inc. - Observation priority e short - lebrikizumab - atopic dermatitis
Eli Lilly and Company - Mirikizumab LY3074828 pro uc cd - omvoh - ulcerative colitis
Eli Lilly and Company - Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Celgene Corporation · Completed · NCT03440385 - M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.